[Latest] Global Pulp and Paper Automation Market Size/Share Worth USD 12.4 Billion by 2032 at a 6.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
October 02, 2023 17:30 ET
|
Custom Market Insights
Austin, TX, USA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Pulp and Paper Automation Market Size, Trends and Insights By Product...
Managing director shares NordLayer’s road to innovation
September 19, 2023 11:31 ET
|
NordLayer
LONDON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- As businesses, governments, and individuals continue to digitize their operations, innovators are tirelessly working to develop cutting-edge solutions that...
RetinalGeniX Technologies Inc. Focuses on Prevention of Blindness and Early Detection of Multiple Systemic Diseases
September 18, 2023 05:59 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) released to the public via OTC Markets, a video webinar regarding...
Neuromeka Participates in FABTECH 2023, Unveiling 3D Vision Collaborative Robot Welding Solution
September 13, 2023 18:45 ET
|
Neuromeka USA, Inc.
CHICAGO, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Neuromeka unveiled its collaborative robot welding solution during FABTECH 2023, North America's largest metal forming, fabricating, welding and finishing...
NordLayer named a finalist at the SaaS Awards and Computing Security Awards 2023
September 04, 2023 12:30 ET
|
NordLayer
LONDON, Sept. 04, 2023 (GLOBE NEWSWIRE) -- NordLayer not only has secured its place as a finalist in the prestigious 2023 SaaS Awards program, competing in the category of Best Security Innovation...
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
August 28, 2023 07:00 ET
|
ONL Therapeutics
More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 Ophthalmic Solution as adjunct to standard-of-care surgery Topline data readout...
RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS
August 28, 2023 06:35 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the...
RetinalGeniX Technologies Inc. Granted Patent for Patient Home Monitoring and Physician Alert System for Ocular Anatomy
July 28, 2023 13:24 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), this week was granted a patent for its Patient Home Monitoring...
Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression
July 11, 2023 09:00 ET
|
Nacuity Pharmaceuticals, Inc.
New clinical site added and early safety signals observed in trial for treatment of ocular disease caused by oxidative stress First cohort is expected to achieve full enrollment by third quarter...
RetinalGeniX Technologies, Inc. Nears Completion of Institutional Review Board for Research on DNA/GPS Program
June 26, 2023 06:15 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today previewed the completion of an Institutional Review Board...